Keytruda And FDA’s Oncology Center of Excellence: The Regulatory Milestones Keep Coming

Merck’s anti-PD-1 therapy Keytruda keeps piling up new indications, including three approved by US FDA in just two weeks – all during a pandemic. The remarkable therapy has been a centerpiece for an equally remarkable period of regulatory innovation.